IGMS

6.90

2.13% -0.15

Dopo l'orario di chiusura: 6.90

Igm Biosciences Inc (IGMS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$7.05

Aprire:

$6.88

Volume 24 ore:

419.38K

Relative Volume:

1.53

Capitalizzazione di mercato:

$410.30M

Reddito:

$2.91M

Utile/perdita netta:

$-220.40M

Rapporto P/E:

-1.3093

EPS:

-5.27

Flusso di cassa netto:

$-176.15M

1 W Prestazione:

-3.77%

1M Prestazione:

-29.34%

6M Prestazione:

+5.99%

1 anno Prestazione:

-12.21%

Intervallo 1D:

$6.755

$7.50

Intervallo di 1 settimana:

$6.755

$7.86

Portata 52W:

$6.1721

$22.50

Igm Biosciences Inc Stock (IGMS) Company Profile

Nome

Igm Biosciences Inc

Settore

Healthcare (1176)

Industria

Biotechnology (673)

Telefono

650-965-7873

Indirizzo

325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW

Dipendente

198

Cinguettio

Prossima data di guadagno

2024-11-11

Ultimi documenti SEC

IGMS's Discussions on Twitter

Confronta IGMS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
IGMS Igm Biosciences Inc	6.90	410.30M	2.91M	-220.40M	-176.15M	-3.64
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-06	Iniziato	BMO Capital Markets	Outperform
2024-10-01	Downgrade	JP Morgan	Neutral → Underweight
2024-10-01	Downgrade	Truist	Buy → Hold
2024-02-09	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2023-12-15	Downgrade	BofA Securities	Buy → Neutral
2023-12-07	Downgrade	H.C. Wainwright	Buy → Neutral
2022-11-09	Ripresa	Jefferies	Buy
2022-10-17	Iniziato	JP Morgan	Neutral
2022-08-29	Iniziato	BofA Securities	Buy
2021-12-13	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2021-11-05	Aggiornamento	Wedbush	Neutral → Outperform
2021-08-26	Iniziato	Morgan Stanley	Overweight
2021-01-29	Iniziato	RBC Capital Mkts	Outperform
2021-01-19	Reiterato	H.C. Wainwright	Buy
2020-12-22	Downgrade	Wedbush	Outperform → Neutral
2020-07-17	Iniziato	Robert W. Baird	Outperform
2020-07-01	Iniziato	H.C. Wainwright	Buy
2020-05-28	Iniziato	SunTrust	Buy
2020-04-22	Iniziato	Wedbush	Outperform
2019-10-14	Iniziato	Guggenheim	Buy
2019-10-14	Iniziato	Jefferies	Buy
2019-10-14	Iniziato	Piper Jaffray	Overweight
2019-10-14	Iniziato	Stifel	Buy

Mostra tutto

Igm Biosciences Inc Borsa (IGMS) Ultime notizie

Dec 18, 2024

IGM Biosciences, Inc. (NASDAQ:IGMS) CEO Mary Beth Harler Sells 1,708 Shares - MarketBeat

Dec 18, 2024

Igm biosciences principal accounting officer sells shares for $4,031 - Investing.com

Dec 18, 2024

Igm biosciences CEO sells $12,775 in stock - Investing.com

Dec 18, 2024

IGM Biosciences chief business officer sells shares worth $7,951 By Investing.com - Investing.com Canada

Dec 18, 2024

IGM Biosciences (NASDAQ:IGMS shareholders incur further losses as stock declines 21% this week, taking five-year losses to 84% - Simply Wall St

Dec 18, 2024

Brokerages Set IGM Biosciences, Inc. (NASDAQ:IGMS) Target Price at $17.75 - Defense World

Dec 18, 2024

Dec 15, 2024

IGM Biosciences, Inc. (NASDAQ:IGMS) Receives $17.75 Average Target Price from Analysts - MarketBeat

Dec 15, 2024

Dec 14, 2024

IGM Biosciences' SWOT analysis: stock pivot to autoimmune focus sparks analyst optimism - Investing.com Australia

Dec 14, 2024

IGM Biosciences' SWOT analysis: stock pivot to autoimmune focus sparks analyst optimism By Investing.com - Investing.com South Africa

Dec 14, 2024

Dec 08, 2024

BMO Capital Markets Begins Coverage on IGM Biosciences (NASDAQ:IGMS) - Defense World

Dec 08, 2024

IGM Biosciences (NASDAQ:IGMS) Shares Gap Up – Here’s What Happened - Defense World

Dec 08, 2024

Dec 07, 2024

IGM Biosciences (NASDAQ:IGMS) Shares Gap UpStill a Buy? - MarketBeat

Dec 07, 2024

BMO Capital Initiates Coverage of IGM Biosciences (IGMS) with Outperform Recommendation - MSN

Dec 07, 2024

Dec 06, 2024

IGM Biosciences (NASDAQ:IGMS) Coverage Initiated by Analysts at BMO Capital Markets - MarketBeat

Dec 06, 2024

Dec 05, 2024

BMO sets $21 target for IGM Biosciences with Outperform rating By Investing.com - Investing.com UK

Dec 05, 2024

Dec 04, 2024

IGM Biosciences: Dizzying Number Of Pivots (NASDAQ:IGMS) - Seeking Alpha

Dec 04, 2024

Dec 02, 2024

Quest Partners LLC Decreases Stock Position in IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World

Dec 02, 2024

Nov 30, 2024

Brokerages Set IGM Biosciences, Inc. (NASDAQ:IGMS) Price Target at $16.13 - MarketBeat

Nov 20, 2024

IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World

Nov 20, 2024

Nov 15, 2024

Will Imvotamab Data Propel IGM Biosciences To New Heights In 2025? - RTTNews

Nov 15, 2024

Nov 13, 2024

How To Trade (IGMS) - Stock Traders Daily

Nov 13, 2024

FMR LLC Increases Stake in IGM Biosciences Inc - GuruFocus.com

Nov 13, 2024

Nov 12, 2024

IGM Biosciences Insiders Who Sold Avert US$165m Market Cap Dip - Simply Wall St

Nov 12, 2024

Nov 11, 2024

Biotech firm backs off its focus on oncology research - The Business Journals

Nov 11, 2024

IGM Biosciences (NASDAQ:IGMS) Given New $27.00 Price Target at Stifel Nicolaus - MarketBeat

Nov 11, 2024

Igm Biosciences: Navigating Financial Challenges Amidst Early-Stage Antibody Development - MSN

Nov 11, 2024

Nov 10, 2024

IGM Biosciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 10, 2024

Nov 09, 2024

IGM Biosciences (NASDAQ:IGMS) Shares Down 7.8%Here's Why - MarketBeat

Nov 09, 2024

Nov 08, 2024